Walking Briskly May Outperform Jogging in Prediabetes

Share this content:
Walking Briskly May Outperform Jogging in Prediabetes
Walking Briskly May Outperform Jogging in Prediabetes

THURSDAY, July 21, 2016 (HealthDay News) -- Brisk walking may be more effective than jogging in controlling blood glucose levels in patients with prediabetes, according to a study published online July 15 in Diabetologia.

The study included 150 individuals with prediabetes who were divided into four groups. One group followed a gold-standard program that included a low-fat, low-calorie diet and moderate-intensity exercise equivalent to 7.5 miles of brisk walking a week. The other participants were assigned to one of three exercise groups: low amount at moderate intensity equivalent to walking briskly for 7.5 miles a week; high amount at moderate intensity equal to walking briskly for 11.5 miles weekly; and high amount at vigorous intensity equivalent to jogging for 11.5 miles a week.

After six months, patients using the three-pronged approach had an average 9 percent improvement in oral glucose tolerance. Among those who did exercise only, there was a 7 percent improvement in the moderate-intensity, 11.5-mile group; a 5 percent improvement in the moderate-intensity, 7.5-mile group; and a 2 percent improvement in the vigorous-intensity, 11.5-mile group.

"When faced with the decision of trying to do weight loss, diet, and exercise versus exercise alone, the study indicates you can achieve nearly 80 percent of the effect of doing all three with just a high amount of moderate-intensity exercise," lead author William Kraus, M.D., of the Duke University School of Medicine in Durham, N.C., said in a journal news release. "I was heartened by the fact that I found out that I can give patients one message and they can get nearly the same effect as when required to exercise, diet, and lose weight all at the same time."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »